Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

153

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	61.46L 71.16L 56.63L 53.01L 99.35L 68Cr 1.01Cr 6.69Cr 2.61Cr 33Cr 2.67Cr 2.61Cr 113.99Cr	P/E Ratio 2023	-3.09x	P/E Ratio 2024	-0.95x
Enterprise Value	5.92Cr 6.86Cr 5.46Cr 5.11Cr 9.58Cr 652Cr 9.73Cr 64Cr 25Cr 317.35Cr 26Cr 25Cr 1.1TCr	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

07/01	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
07/01	CARMAT: To Watch Today
06/01	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
06/01	Carmat Announces Liquidation and Delisting
02/12	Only Takeover Bid for Carmat Approved by Court
02/12	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
02/12	Carmat receives takeover bid	RE
04/11	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
15/25/15	CAC 40 Surges on LVMH Results and Easing US-China Tensions
15/25/15	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
15/25/15	Carmat says liquidation review postponed until Nov 25	RE
01/25/01	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE
01/25/01	Carmat: Judiciary administrator has submitted request to convert receivership into liquidation to court	RE

09/25/09	Carmat: Invest Securities raises target price
11/25/11	Carmat: Invest Securities still a buyer, but cuts TP
04/25/04	Carmat: Invest Securities slightly lowers its target
09/25/09	Carmat: Invest Securities upgrades to buy
09/25/09	Carmat: Oddo BHF reduces its price target

02/12	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
04/11	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
29/25/29	CARMAT : Inside Information / Other news releases	PU
29/25/29	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
15/25/15	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

04/03	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
07/01	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
07/01	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
07/01	CARMAT : A suivre aujourd'hui
07/01	Les records continuent à tomber en bourse

CARMAT Share Price OTC Markets

Stocks

CKMTF

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation: CARMAT

Latest news : CARMAT

Analysts' recommendations: CARMAT

Press Releases: CARMAT

News in other languages: CARMAT

Quotes and Performance

Managers and Directors: CARMAT

Medical Devices & Implants

Financials

Company Profile

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	01/09/2016
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	12/12/2018
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	01/04/2025

Director	Title	Age	Since
Stéphane Piat BRD	Director/Board Member	55	-
Jean-Luc Lemercier BRD	Director/Board Member	68	02/01/2017
Michael Mack BRD	Director/Board Member	79	20/04/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-50.96%	-54.87%	-	-	70.8L
STRYKER CORPORATION	+2.19%	+2.25%	-17.86%	+11.65%	12TCr
SMITH & NEPHEW PLC	-0.31%	-1.22%	+2.12%	-4.39%	1.29TCr
GLAUKOS CORPORATION	+1.86%	+1.32%	+29.76%	+89.23%	729.48Cr
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+1.87%	-3.51%	-46.74%	-69.06%	411.68Cr
DOUBLE MEDICAL TECHNOLOGY INC.	+2.06%	+5.59%	+11.04%	+33.01%	249.16Cr
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+5.46%	+10.30%	-16.96%	-14.78%	170.1Cr
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+1.67%	-6.39%	+3.63%	-11.43%	163.04Cr
L&C BIO CO.,LTD	-8.89%	-8.45%	+165.17%	+112.14%	148.75Cr
Average	-4.99%	+1.07%	+16.27%	+18.30%	1.86TCr
Weighted average by Cap.	+1.84%	+1.39%	-12.04%	+12.64%

	2023	2024
Net sales	38.37L 44.43L 35.36L 33.1L 62.03L 42Cr 62.99L 4.17Cr 1.63Cr 21Cr 1.67Cr 1.63Cr 71Cr	73.44L 85.03L 67.67L 63.35L 1.19Cr 81Cr 1.21Cr 7.99Cr 3.12Cr 39Cr 3.19Cr 3.12Cr 136.21Cr
Net income	-5.39Cr -6.24Cr -4.96Cr -4.65Cr -8.71Cr -592.83Cr -8.84Cr -59Cr -23Cr -288.55Cr -23Cr -23Cr -999.11Cr	-5.14Cr -5.95Cr -4.74Cr -4.43Cr -8.31Cr -565.6Cr -8.44Cr -56Cr -22Cr -275.3Cr -22Cr -22Cr -953.23Cr
Net Debt	4.96Cr 5.75Cr 4.57Cr 4.28Cr 8.02Cr 546.25Cr 8.15Cr 54Cr 21Cr 265.88Cr 22Cr 21Cr 920.6Cr	5.31Cr 6.15Cr 4.89Cr 4.58Cr 8.58Cr 584.37Cr 8.72Cr 58Cr 23Cr 284.43Cr 23Cr 23Cr 984.85Cr